Notice of Allowability	Application No.	tion No. Applicant(s)	
	10/591,883	SWANSON ET AL.	
	Examiner	Art Unit	
	Thaian N. Ton	1632	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. \square This communication is responsive to $\underline{1/10/11}$.			
2. The allowed claim(s) is/are <u>4-8,10,11 and 34</u> .			
 3. Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 	been received.		
2. Certified copies of the priority documents have	• •		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the			
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.			
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached			
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
Attachment(s) 1. Notice of References Cited (PTO-892)	5. ☐ Notice of Inf	ormal Patent Application	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)		mmary (PTO-413),	
3. ☐ Information Disclosure Statements (PTO/SB/08),	Paper No./I	Mail Date <u>1/21/11</u> . Amendment/Comment	
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	8. ☐ Examiner's \$	Statement of Reasons for Allowance	
of Biological Material	9. 🗌 Other		
/Thaian N. Ton/			
Primary Examiner, Art Unit 1632			

Application/Control Number: 10/591,883 Page 2

Art Unit: 1632

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Melissa Hunter-Ensor on January 21, 2011.

The application has been amended as follows:

- 1. Replace claim 4 with the following:
- 4. The method of claim 34, wherein treating comprises reducing the mis-splicing of the Clcn1 skeletal muscle chloride channel gene.
 - 2. Replace claim 5 with the following:
 - 5. The method of claim 34, wherein treating comprises reducing the mis-splicing of the Amyloid beta (A4) precursor protein (APP) gene.
 - 3. Replace claim 6 with the following:
- 6. The method of claim 34, wherein treating comprises reducing the mis-splicing of the NMDA receptor NR1 (GRIN1) gene.
 - 4. Replace claim 7 with the following:
- 7. The method of claim 34, wherein treating comprises reducing the mis-splicing of the Microtubule-associated protein tau (MAPT) gene.
 - 5. Replace claim 8 with the following:
- 8. The method of claim 34, wherein treating comprises reducing the mis-splicing of the TNNT2 (cTNT) gene.
- 6. The title has been changed to "Methods and Compositions For Treatment of Myotonia".

Application/Control Number: 10/591,883

Art Unit: 1632

Page 3

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thaian N. Ton whose telephone number is (571)272-0736. The examiner can normally be reached on 9-5:30 M·F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Thaian N. Ton/ Primary Examiner, Art Unit 1632